On the Move (Company Changes and Promotions) (1/07)
Executive SummaryWho went where? In Vivo notes significant recent job changes at medical product companies and other firms in the life sciences industries.
You may also be interested in...
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.